Systemic therapies for salivary gland carcinoma (excluding adenoid cystic carcinoma) : REFCOR recommendations by the formal consensus method
Copyright © 2023 Elsevier Masson SAS. All rights reserved..
OBJECTIVE: To determine the therapeutic indications for systemic medical treatment in the management of salivary gland carcinoma (excluding adenoid cystic carcinoma) according to the clinical situation.
MATERIALS AND METHODS: The French Network of Rare Head and Neck Tumors (REFCOR) formed a steering group who drafted a narrative review of the literature published on Medline and proposed recommendations. The level of adherence to the recommendations was then assessed by a rating group, according to the formal consensus method.
RESULTS: Salivary gland carcinoma is rare and there is currently insufficient evidence to indicate chemotherapy at the localized stage. At the metastatic stage, initial management can be based on a phase of monitoring for indolent disease. Some histological subtypes (salivary duct carcinoma and adenocarcinoma) are more aggressive and require systemic treatment from the outset. To guide systemic treatment, it is recommended to perform immunohistochemistry and molecular biology analyses (overexpression of HER2 and androgen receptors, NTRK fusion, next-generation sequencing).
CONCLUSION: Salivary gland carcinoma is a rare tumor for which there are currently few effective medical treatments. It is therefore recommended to include patients in clinical trials.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
European annals of otorhinolaryngology, head and neck diseases - (2023) vom: 30. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sarradin, V [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chemotherapy |
|---|
| Anmerkungen: |
Date Revised 01.12.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.anorl.2023.11.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365315885 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365315885 | ||
| 003 | DE-627 | ||
| 005 | 20231226101414.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.anorl.2023.11.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1217.xml |
| 035 | |a (DE-627)NLM365315885 | ||
| 035 | |a (NLM)38040592 | ||
| 035 | |a (PII)S1879-7296(23)00156-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sarradin, V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Systemic therapies for salivary gland carcinoma (excluding adenoid cystic carcinoma) |b REFCOR recommendations by the formal consensus method |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2023 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a OBJECTIVE: To determine the therapeutic indications for systemic medical treatment in the management of salivary gland carcinoma (excluding adenoid cystic carcinoma) according to the clinical situation | ||
| 520 | |a MATERIALS AND METHODS: The French Network of Rare Head and Neck Tumors (REFCOR) formed a steering group who drafted a narrative review of the literature published on Medline and proposed recommendations. The level of adherence to the recommendations was then assessed by a rating group, according to the formal consensus method | ||
| 520 | |a RESULTS: Salivary gland carcinoma is rare and there is currently insufficient evidence to indicate chemotherapy at the localized stage. At the metastatic stage, initial management can be based on a phase of monitoring for indolent disease. Some histological subtypes (salivary duct carcinoma and adenocarcinoma) are more aggressive and require systemic treatment from the outset. To guide systemic treatment, it is recommended to perform immunohistochemistry and molecular biology analyses (overexpression of HER2 and androgen receptors, NTRK fusion, next-generation sequencing) | ||
| 520 | |a CONCLUSION: Salivary gland carcinoma is a rare tumor for which there are currently few effective medical treatments. It is therefore recommended to include patients in clinical trials | ||
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Chemotherapy | |
| 650 | 4 | |a Locally advanced disease | |
| 650 | 4 | |a Metastatic disease | |
| 650 | 4 | |a Salivary gland cancer | |
| 650 | 4 | |a Systemic therapy | |
| 700 | 1 | |a Digue, L |e verfasserin |4 aut | |
| 700 | 1 | |a Vergez, S |e verfasserin |4 aut | |
| 700 | 1 | |a Thariat, J |e verfasserin |4 aut | |
| 700 | 1 | |a Fakhry, N |e verfasserin |4 aut | |
| 700 | 1 | |a Chabrillac, E |e verfasserin |4 aut | |
| 700 | 1 | |a Bensadoun, R-J |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrand, F-R |e verfasserin |4 aut | |
| 700 | 1 | |a Even, C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European annals of otorhinolaryngology, head and neck diseases |d 2010 |g (2023) vom: 30. Nov. |w (DE-627)NLM201398648 |x 1879-730X |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:30 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.anorl.2023.11.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 30 |c 11 | ||